|Tested species reactivity||Horse, Human, Mouse, Non-human primate, Rat|
|Host / Isotype||Rabbit / IgG|
|Immunogen||Portion of amino acid 580-630 of human NLRX1|
|Storage buffer||PBS with 0.05% BSA|
|Contains||0.05% sodium azide|
|Storage Conditions||Store at 4°C short term. For long term storage, store at -20°C, avoiding freeze/thaw cycles.|
|Tested Applications||Dilution *|
|Immunohistochemistry (Paraffin) (IHC (P))||5-10 µg/ml|
|Western Blot (WB)||5-7 µg/ml|
* Suggested working dilutions are given as a guide only. It is recommended that the user titrate the product for use in their own experiment using appropriate negative and positive controls.
NLR family member X1 (NLRX1) belongs to the NLRP family and contains four LRR (leucine-rich) repeats and one NATCH domain. NLRX1 localizes to the mitochondrial outer membrane and interacts through the mitochondrial antiviral signalling adaptor MAVS during viral infection. Expression of NLRX1 results in the potent inhibition of RLH- and MAVS-mediated interferon-beta promoter activity and in the disruption of virus-induced RLH-MAVS interactions. It is also reported that NLRX1 synergistically potentiated ROS production induced by tumour necrosis factor alpha, Shigella infection and double-stranded RNA, resulting in amplified NF-kappaB-dependent and JUN amino-terminal kinases-dependent signalling, thus contributing to the link between ROS generation at the mitochondria and innate immune responses.
For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.